Systemic Inflammation After Drug-Eluting Stent Placement

[1]  Patrick W Serruys,et al.  Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients: An Evaluation From the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Study , 2004, Circulation.

[2]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[3]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[4]  H. Dauerman,et al.  Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. , 2004, The American journal of cardiology.

[5]  H. Dauerman,et al.  Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. , 2003, American Journal of Cardiology.

[6]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[7]  R. Detels,et al.  Analytical Performance of a Highly Sensitive C-Reactive Protein-Based Immunoassay and the Effects of Laboratory Variables on Levels of Protein in Blood , 2003, Clinical Diagnostic Laboratory Immunology.

[8]  William W O'Neill,et al.  Drug-eluting stents: costs versus clinical benefit. , 2003, Circulation.

[9]  P. Serruys,et al.  Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.

[10]  F. Crea,et al.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). , 2002, Journal of the American College of Cardiology.

[11]  Elazer R. Edelman,et al.  Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group , 2002, Circulation.

[12]  K. Ray.  Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. , 2002, Circulation.

[13]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[14]  L. Deckelbaum,et al.  Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization , 2001, Circulation.

[15]  S. Humphries,et al.  Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. , 2000, Cytokine.

[16]  G. Maurer,et al.  Plasma levels of C-reactive protein after coronary stent implantation. , 2000, European heart journal.

[17]  F. Crea,et al.  Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. , 1998, The American journal of cardiology.

[18]  E J Topol,et al.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.